Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Business Update

5 Nov 2008 07:00

RNS Number : 4604H
China Real Estate Opportunities Ltd
05 November 2008
 

5 November 2008

China Real Estate Opportunities Limited

Business Update

China Real Estate Opportunities ("CREO" or the "Company"), an AIM listed property company with an established investment and development property portfolio in China, today provides an update on the Company's trading since 1 July 2008.

 

 Investment Highlights:

Strong Income Producing Portfolio Continues to Outperform

CREO's income producing assets, which represent 75% of the Company's total portfolio, have continued to perform strongly in the third quarter. Three year rollover on leases, which is standard practice in China, has enabled the Company to continue to drive income growth in the short to medium term.

Office: CREO achieved between 10% to 50% rental income growth from lease renewals and new leases since 1 July 2008.

Occupancy rates in the investment assets remain strong:

Central Plaza: 92% 

City Center: 95% 

Treasury Building: 97% 

Retail: CREO has completed 21 lease renewals and new leases since 1 July 2008, and has achieved up to 40% increase in rents on individual transactions and an average of over 16% growth from letting transactions in the period

Development Highlights: 

CREO's development programme continued to make progress throughout the period

Beijing Logistics Park: construction is due to commence in November 2008. Completion of this development project is expected in 2009, and the Company has already received strong leasing enquiries.

Central Plaza: office tower refurbishment work is on schedule for completion before the end of 2008 while the remainder of the refurbishment programme is on track for completion in 2009.

City Center: short-term refurbishment work will be completed in Q1 2009. 

City Center Extension (formerly referred to as CC3): the design and planning process is proceeding as outlined earlier this year.

City Center Development (formerly referred to as CC5): on track to commence in the current quarter. 

Financing

The maturity profile of CREO loans secured against its investment properties remains unchanged with all existing loans locked in until Q3 2010

In addition, CREO has recently secured a new development loan facility from DBS Bank in relation to the construction of its Beijing Logistics Park development.

The Chinese Market: Robust Office & Retail Markets

China's annualised GDP growth in the quarter to September 30 was a strong 9.0%(1) and 9.9% for the year to date(1), highlighting considerable continued momentum and although the prospects for the China economy are not immune to the deteriorating external environment, this growth trend represents a strong foundation for China to weather the current economic upheaval.

China's retail sales increased by 22% in the last nine months(1), underpinning continued strong demand for retail space. In addition, the Shanghai retail rental market continued to enjoy a buoyant performance with growth of 5.7% quarter on quarter, whilst vacancy rates were down by 0.4% in the quarter as demand, in particular from international retail, continues(2).

Shanghai prime office rental performance was stable overall in Q3, following the impact of considerable additional supply in recent months which led to an increase in market vacancy rates(2) during the quarter. Within this context, the CREO portfolio has delivered a strong performance, evidenced by maintained strong occupancy and rental growth in the last quarter.

"During this period of unprecedented market volatility and uncertainty seen in global equity and debt markets, the focus of CREO Directors has been to continue to manage its assets intensively and deliver growth. As a result, the business has continued to perform strongly in the period. CREO's income producing portfolio continues to see significant uplifts in rental income arising from rental reviews and new lettings, reflecting a resilient rental market."

"Activity in the CREO development portfolio continues at pace as construction of the Beijing Logistics Park is about to commence and the planning process for the City Center Extension development is underway. The Company is positioned to continue to perform well in the short and medium term.", commented Ray Horney, CREO Chairman.

(1) PRC National Bureau of Statistics

(2) CBRE China, Q3 2008 MarketView

-----------ENDS---------

  

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Davy

Des Carville

Tel: +353 1 679 6363

Bankside Consultants

Simon Rothschild, Oliver Winters

Tel: + 44 (0)207 367 8888

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSAEELSASEFF
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.